← Leaderboards
James A Wells
University Of California, San Francisco
$24,064,501
Attributed
$24,064,501
Total exposure
33
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,064,501 · 33
By mechanism
R01$12,437,235 · 7
R35$4,506,619 · 1
P41$2,270,993 · 16
R44$1,660,420 · 1
S10$1,100,000 · 2
P30$772,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Charles Scott Craik$31,131,909
- Aimee Kao$26,280,041
- Harold A Chapman$29,865,601
- Diane V Havlir$125,216,731
- Tamara N Alliston$9,755,404
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsProteinsProteomicsSiteEngineeringCaspasePeptide HydrolasesApoptosisTechnologyEventMalignant NeoplasmsLabelSignal TransductionProteolysisPeptidesCleaved CellApoptoticEnzymesMass Spectrum AnalysisNew TechnologyCancer CellDesignBiologyPathway Interactions
Grant awards (81)
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolution$572,243
R35 · FY2025 · GM · contact PI
New protein-engineered tools and technologies for identifying, deorphanizing, and targeting shed proteins in cancer$404,177
R01 · FY2025 · CA · contact PI
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolution$572,243
R35 · FY2024 · GM · contact PI
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets$345,184
R01 · FY2024 · CA · contact PI
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolution$572,243
R35 · FY2023 · GM · contact PI
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets$356,084
R01 · FY2023 · CA · contact PI
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets$356,084
R01 · FY2022 · CA · contact PI
Discovering how oncogenes remodel the surfaceome of cells$534,869
R35 · FY2021 · GM · contact PI
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets$363,351
R01 · FY2021 · CA · contact PI
Discovering how oncogenes remodel the surfaceome of cells$534,869
R35 · FY2020 · GM · contact PI
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targets$362,803
R01 · FY2020 · CA · contact PI
Discovering how oncogenes remodel the surfaceome of cells$534,869
R35 · FY2019 · GM · contact PI
Discovering how oncogenes remodel the surfaceome of cells$534,869
R35 · FY2018 · GM · contact PI
Affinity-directed tagging of protein binding partners in signaling$328,888
R01 · FY2018 · CA · contact PI
Renewable Antibodies for Post Translational Modifications and Protease Activatio$320,476
P41 · FY2018 · CA · contact PI
Discovering how oncogenes remodel the surfaceome of cells$115,545
R35 · FY2018 · GM · contact PI
Discovering how oncogenes remodel the surfaceome of cells$534,869
R35 · FY2017 · GM · contact PI
Affinity-directed tagging of protein binding partners in signaling$328,888
R01 · FY2017 · CA · contact PI
Renewable Antibodies for Post Translational Modifications and Protease Activatio$327,694
P41 · FY2017 · CA · contact PI
Renewable Antibodies for Post Translational Modifications and Protease Activatio$334,881
P41 · FY2016 · CA · contact PI
Affinity-directed tagging of protein binding partners in signaling$328,888
R01 · FY2016 · CA · contact PI
Renewable Antibodies for Post Translational Modifications and Protease Activatio$341,955
P41 · FY2015 · CA · contact PI
Affinity-directed tagging of protein binding partners in signaling$328,801
R01 · FY2015 · CA · contact PI
Global Analysis of Proteolysis in Apoptosis$303,061
R01 · FY2015 · GM · contact PI
Generation of recombinant thiopeptides to target antimicrobial-resistant bacteria$192,846
R21 · FY2015 · AI · contact PI
Renewable Antibodies for Post Translational Modifications and Protease Activatio$797,520
P41 · FY2014 · CA · contact PI
Affinity-directed tagging of protein binding partners in signaling$327,677
R01 · FY2014 · CA · contact PI
Approaches to discover and quantify apoptotic biomarkers for cancer treatment$310,970
R01 · FY2014 · CA · contact PI
Global Analysis of Proteolysis in Apoptosis$302,253
R01 · FY2014 · GM · contact PI
Regulating Proteolysis to Dissect Apoptosis$285,442
R01 · FY2014 · GM · contact PI
Generation of recombinant thiopeptides to target antimicrobial-resistant bacteria$220,814
R21 · FY2014 · AI · contact PI
Approaches to discover and quantify apoptotic biomarkers for cancer treatment$301,352
R01 · FY2013 · CA · contact PI
Direct Chemical Activators of Caspases$292,312
R01 · FY2013 · CA · contact PI
Global Analysis of Proteolysis in Apoptosis$290,045
R01 · FY2013 · GM · contact PI
Regulating Proteolysis to Dissect Apoptosis$275,452
R01 · FY2013 · GM · contact PI
Automated System for High-Throughput In Vitro Selection of Recombinant Antibodies$600,000
S10 · FY2012 · OD · contact PI
Approaches to discover and quantify apoptotic biomarkers for cancer treatment$320,588
R01 · FY2012 · CA · contact PI
Direct Chemical Activators of Caspases$310,970
R01 · FY2012 · CA · contact PI
Global Analysis of Proteolysis in Apoptosis$299,611
R01 · FY2012 · GM · contact PI
Regulating Proteolysis to Dissect Apoptosis$285,442
R01 · FY2012 · GM · contact PI
Site-specific Allosteric Inhibitors for Inflammatory Caspases$371,372
R01 · FY2011 · AI · contact PI
Approaches to discover and quantify apoptotic biomarkers for cancer treatment$320,588
R01 · FY2011 · CA · contact PI
Direct Chemical Activators of Caspases$310,970
R01 · FY2011 · CA · contact PI
Global Analysis of Proteolysis in Apoptosis$287,709
R01 · FY2011 · GM · contact PI
Regulating Proteolysis to Dissect Apoptosis$285,442
R01 · FY2011 · GM · contact PI
SENSITIVE GLOBAL PROFILING OF PROTEOLYSIS IN APOPTOSIS$52,433
P41 · FY2011 · RR · contact PI
IDENTIFYING THE ROLE OF CASPASE-MEDIATED PROTEOLYSIS ON INFLAMMATION$12,740
P41 · FY2011 · RR · contact PI
IDENTIFICATION OF CASPASE-2 SUBSTRATES$9,708
P41 · FY2011 · RR · contact PI
PROTEOMIC ANALYSIS OF APOPTOTIC PROTEIN CLEAVAGES IN DROSOPHILA MELANOGASTER$3,860
P41 · FY2011 · RR · contact PI
PROTEOMIC IDENTIFICATION OF PROTEIN N-TERMINI IN BLOOD PLASMA AND SERUM$33
P41 · FY2011 · RR · contact PI
IDENTIFICATION OF PROTEOLYSIS-DEPENDENT EXECUTIONER CASPASE PROTEIN COMPLEXES$17
P41 · FY2011 · RR · contact PI
Start-up Funds for Junior Faculty in Chemical Biology Group at UCSF$386,250
P30 · FY2010 · GM · contact PI
Site-specific Allosteric Inhibitors for Inflammatory Caspases$375,123
R01 · FY2010 · AI · contact PI
Direct Chemical Activators of Caspases$320,588
R01 · FY2010 · CA · contact PI
Global Analysis of Proteolysis in Apoptosis$290,615
R01 · FY2010 · GM · contact PI
Global Analysis of Proteolysis in Apoptosis$146,775
R01 · FY2010 · GM · contact PI
IDENTIFYING THE ROLE OF CASPASE-MEDIATED PROTEOLYSIS ON INFLAMMATION$26,497
P41 · FY2010 · RR · contact PI
SENSITIVE GLOBAL PROFILING OF PROTEOLYSIS IN APOPTOSIS$8,832
P41 · FY2010 · RR · contact PI
PROTEOMIC IDENTIFICATION OF PROTEIN N-TERMINI IN BLOOD PLASMA AND SERUM$7,066
P41 · FY2010 · RR · contact PI
IDENTIFICATION OF CASPASE-2 SUBSTRATES$7,066
P41 · FY2010 · RR · contact PI
High-throughput SPR Instrument for Small Molecule Discovery$500,000
S10 · FY2009 · RR · contact PI
Start-up Funds for Junior Faculty in Chemical Biology Group at UCSF$386,250
P30 · FY2009 · GM · contact PI
Site-specific Allosteric Inhibitors for Inflammatory Caspases$378,911
R01 · FY2009 · AI · contact PI
Direct Chemical Activators of Caspases$311,257
R01 · FY2009 · CA · contact PI
Global Analysis of Proteolysis in Apoptosis$293,550
R01 · FY2009 · GM · contact PI
SENSITIVE GLOBAL PROFILING OF PROTEOLYSIS IN COMPLEX BIOCHEMICAL MIXTURES$6,553
P41 · FY2009 · RR · contact PI
IDENTIFYING THE ROLE OF CASPASE-MEDIATED PROTEOLYSIS ON INFLAMMATION$2,406
P41 · FY2009 · RR · contact PI
PROTEOMIC IDENTIFICATION OF PROTEIN N-TERMINI IN BLOOD PLASMA AND SERUM$507
P41 · FY2009 · RR · contact PI
Site-specific Allosteric Inhibitors for Inflammatory Caspases$378,503
R01 · FY2008 · AI · contact PI
Global Analysis of Proteolysis in Apoptosis$293,313
R01 · FY2008 · GM · contact PI
SENSITIVE GLOBAL PROFILING OF PROTEOLYSIS IN COMPLEX BIOCHEMICAL MIXTURES$10,348
P41 · FY2008 · RR · contact PI
Site-specific Allosteric Inhibitors for Inflammatory Caspases$384,583
R01 · FY2007 · AI · contact PI
Global Analysis of Proteolysis in Apoptosis$279,613
R01 · FY2007 · GM · contact PI
SENSITIVE GLOBAL PROFILING OF PROTEOLYSIS IN APOPTOSIS$401
P41 · FY2007 · RR · contact PI
Activators of Procaspase-7$191,875
R21 · FY2006 · NS · contact PI
HIV Integrase Drug Discovery Using Tethering Technology$299,999
R43 · FY2003 · AI
New Advances in Drug Discovery$2,000
R13 · FY2003 · CA
SITE-DIRECTED DRUG DISCOVERY$526,420
R44 · FY2002 · CA
HIV Integrase Drug Discovery Using Tethering Technology$300,000
R43 · FY2002 · AI
SITE-DIRECTED DRUG DISCOVERY$1,134,000
R44 · FY2001 · CA
METHOD FOR DRUG DISCOVERY USING FRAGMENT ASSEMBLY$109,200
R43 · FY2000 · CA